PFE - Pfizer Inc.

NYSE - NYSE Delayed price. Currency in USD
33.83
+0.37 (+1.11%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous close33.46
Open33.66
Bid33.81 x 3000
Ask33.83 x 2200
Day's range33.49 - 34.04
52-week range27.88 - 43.23
Volume22,036,999
Avg. volume27,887,676
Market cap187.92B
Beta (5Y monthly)0.68
PE ratio (TTM)12.09
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.52 (4.54%)
Ex-dividend date30 Jul 2020
1y target estN/A
All
News
Press releases
  • Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
    Business Wire

    Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance

    Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.

  • GlobeNewswire

    Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

    In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2.

  • Pfizer Declares Third-Quarter 2020 Dividend
    Business Wire

    Pfizer Declares Third-Quarter 2020 Dividend

    The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of record at the close of business on July 31, 2020. The third-quarter 2020 cash dividend will be the 327th consecutive quarterly dividend paid by Pfizer.

  • Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
    Business Wire

    Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa

    Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private research collaboration with the governments of Ghana, Kenya, Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance (AMR) on patients living in low- and middle-income countries. This first-of-its kind partnership will provide governments and health authorities with comprehensive data in four sub-Saharan African countries where there is a high burden of infectious diseases, insufficient data and lack of capacity to implement critically needed infection prevention and control programs.

  • Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
    Business Wire

    Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines

    Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines:

  • Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
    Business Wire

    Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

    Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVIII infusions. The factor VIII activity levels reflect measurements up to 61 weeks, the extent of follow-up for the longest-treated patient in the cohort. These data are being presented today as a late-breaking oral abstract at the World Federation of Hemophilia 2020 World Congress, which is being held virtually from June 14 to June 19, 2020.

  • Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
    Business Wire

    Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn

    Upjohn Inc. ("Newco"), a wholly-owned subsidiary of Pfizer Inc. ("Pfizer") (NYSE: PFE), Upjohn Finance B.V. ("Finco"), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. ("Mylan") (Nasdaq: MYL) today announced the pricing of a private offering of $7.45 billion aggregate principal amount of Newco’s senior, U.S. dollar-denominated notes (collectively, the "U.S. Dollar Notes") and a private offering of €3.60 billion aggregate principal amount of Finco’s senior, euro-denominated notes (collectively, the "Euro Notes" and, together with the U.S. Dollar Notes, the "Notes"), comprised of:

  • Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Business Wire

    Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

    Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO Meets Primary Endpoint in VERTIS CV Trial for Patients with Type2 Diabetes and Atherosclerotic CV Disease

  • Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
    Business Wire

    Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

    Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2020. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2020 Performance Report, to be issued that morning.

  • Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
    Business Wire

    Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th

    Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Thursday, June 18, 2020 at 11:30 a.m. EDT. The purpose of the call is to review the data presented at the American Diabetes Association 80th Scientific Sessions held on June 12-16, 2020 on our oral small molecule GLP-1R agonist (PF-06882961) and at the World Federation of Hemophilia Virtual Summit held on June 14-19, 2020 on the Alta Hemophilia A Gene Therapy Study (partnered with Sangamo Therapeutics, Inc.).

  • FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
    Business Wire

    FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)

    Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA™ (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.2

  • Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
    Business Wire

    Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis

    Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 to <18 years of age with moderate to severe atopic dermatitis (AD) who were also on background topical therapy. Both doses of abrocitinib met the co-primary endpoints and were generally well tolerated.

  • Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology
    Business Wire

    Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology

    Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). Consistent with the first Phase 3 monotherapy study (JADE MONO-1), both doses of abrocitinib met all co-primary and key secondary endpoints and were generally well tolerated.

  • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
    Business Wire

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:20 p.m. EDT.

  • Pfizer Establishes New Program to Support Continued Biotechnology Innovation
    Business Wire

    Pfizer Establishes New Program to Support Continued Biotechnology Innovation

    Pfizer Inc. (NYSE: PFE) today announced the establishment of the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and access to Pfizer’s scientific expertise to ensure continuity of the biotechnology companies’ most promising clinical development programs.

  • Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
    Business Wire

    Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

    As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps by their physicians and long-term follow up of all patients will proceed as planned. No unexpected new safety signals were observed in patients receiving palbociclib.

  • GlobeNewswire

    Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging

    The multiyear agreement provides for the supply of Valor Glass vials to a portion of currently marketed Pfizer drug products, pending regulatory approval. Since first launching its collaboration with Corning, Pfizer has continued to evaluate Valor Glass’ performance across several aseptic sites, utilizing multiple vial sizes, with a broad range of drug products from Pfizer’s sterile injectables portfolio. During this time, Valor Glass was accepted into and provisionally evaluated under the Food and Drug Administration’s (FDA) Emerging Technology Program.

  • GlobeNewswire

    ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (PFE) has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020. The private placement is contingent upon the closing of ContraFect’s public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.

  • Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
    Business Wire

    Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC

    Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162.5 million principal amount of Pfizer’s outstanding 7.200% notes due 2039 (the "Pfizer Notes") and up to $130.0 million principal amount of Wyeth’s 5.950% notes due 2037 (the "Wyeth Notes" and together with the Pfizer Notes, the "Notes"). Wyeth is a wholly-owned subsidiary of Pfizer. Pfizer and Wyeth do not endorse Offeror’s unsolicited tender offer, and neither Pfizer nor Wyeth is affiliated or associated with the Offeror, the tender offer or the offer documentation. The Offeror did not inform Pfizer of the tender offer, and Pfizer only became aware of the offer through a third party source. Further, there is no disclosure of information regarding the Offeror or any indication as to a source of financing for the offer in the offer documentation.

  • Pfizer Prices $4,000,000,000 Debt Offering
    Business Wire

    Pfizer Prices $4,000,000,000 Debt Offering

    Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:

  • Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
    Business Wire

    Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study

    Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary data from 9 ambulatory boys with DMD, aged 6 to 12 (mean age: 8 years) indicate that the intravenous administration of PF-06939926 was well-tolerated during the infusion period, with encouraging efficacy and manageable safety events, even when considering those adverse events that were more severe in nature. The treatment provided durable and statistically significant improvements across multiple efficacy-related endpoints measured at 12 months post-infusion, including sustained levels of mini-dystrophin expression and improvements on the North Star Ambulatory Assessment (NSAA) rating scale, which is a validated measure of muscle function. Three serious adverse events (SAEs) were recorded, two of which reflected likely complement activation. While these two SAEs were severe in nature, all three events fully resolved within 2 weeks, providing encouragement that close monitoring and early intervention can help mitigate the effects of complement activation. This new dataset, which includes updated 12-month results on safety, dystrophin expression, and exploratory functional endpoints for 3 additional boys, was presented for the first time during a virtual oral session today at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

  • Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
    Business Wire

    Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

    Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different lots of its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) candidate in adults 18 through 49 years of age not previously vaccinated against pneumococcal disease. Responses elicited by 20vPnC for all 20 serotypes were equivalent across all three lots, meeting the primary immunogenicity objective of the study. In this study the 20vPnC safety profile was similar to the Prevnar 13® (pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) control group. This clinical lot consistency study is expected to satisfy licensure requirements for manufacturing consistency by the U.S. Food and Drug Administration, and other countries’ regulatory agencies.

  • Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
    Business Wire

    Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day

    Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day on Monday, September 14, 2020 at 9:00 a.m. EDT. Pfizer postponed its Investor Day, originally scheduled for March 31, 2020, due to health and safety concerns around the COVID-19 pandemic.

  • New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
    Business Wire

    New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program

    Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from May 29-May 31. The data that will be presented build on Pfizer’s strong track record in oncology by providing new insights in areas like breast, colorectal and genitourinary cancers, which include bladder, prostate, and kidney cancer. Data from Pfizer’s early stage pipeline, including a novel anti-HER2 antibody-drug conjugate, will also be presented as Pfizer aims to transform the cancer treatment landscape well into the future.

  • Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
    Business Wire

    Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting

    Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT. The purpose of the call is to review the DMD data presentation at the American Society of Gene and Cell Therapy (ASGCT) 2020 Annual Meeting.